An open-label extension trial of galantamine in patients with probable vascular dementia and mixed dementia

Clinical Therapeutics

Volumn 25, Issue 6, 2003, Pages 1765-1782

  Erkinjuntti, Timo ^a   Kurz, Alexander ^b   Small, Gary W ^c   Bullock, Roger ^d   Lilienfeld, Sean ^e   Damaraju, C V ^f  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d VICTORIA HOSPITAL   (United Kingdom)

^e JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^f JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Alzheimer's disease; Cerebrovascular; Efficacy; Galantamine; Placebo; Safety

Indexed keywords

CHOLINESTERASE INHIBITOR; GALANTAMINE; NICOTINIC AGENT;

AGED; AGITATION; ALLOSTERISM; ALZHEIMER DISEASE; ARTICLE; BEHAVIOR; BRADYCARDIA; CLINICAL TRIAL; COGNITION; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CONVULSION; DEPRESSION; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; ENZYME INHIBITION; FATIGUE; FEMALE; FUNCTIONAL ASSESSMENT; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MIXED DEPRESSION AND DEMENTIA; MULTIINFARCT DEMENTIA; NAUSEA; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SIDE EFFECT; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; SYNCOPE; VERTIGO; VOMITING;

EID: 0038354968     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(03)80168-6     Document Type: Article

References (33)

1. Pendlebury WW, Solomon PR. Alzheimer's disease. Clin Syrup. 1996;48:2-32.
2. Erkinjuntti T. Cerebrovascular dementia. Pathophysiology, diagnosis and treatment. CNS Drugs. 1999;12:35-48.
3. Rockwood K, Wentzel C, Hachinski V, et al, for the Vascular Cognitive Impairment Investigators of the Canadian Study of Health and Aging. Prevalence and outcomes of vascular cognitive impairment. Neurology. 2000;54:447-451.
4. Jellinger KA. Alzheimer disease and cerebrovascular pathology: An update. J Neural Transm. 2002;109:813-836.
5. Kalaria R. Similarities between Alzheimer's disease and vascular dementia. J Neurol Sci. 2002;203-204:29-34.
6. Rockwood K. Vascular cognitive impairment and vascular dementia. J Neurol Sci. 2002;203-204:23-27.
7. Bartus RT, Dean RL III, Beer B, Lippa AS. The cholinergic hypothesis of geriatric memory dysfunction. Science. 1982;217:408-417.
8. Togashi H, Matsumoto M, Yoshioka M, et al. Neurochemical profiles in cerebrospinal fluid of stroke-prone spontaneously hypertensive rats. Neurosci Lett. 1994;166:117-120.
9. Tanaka K, Ogawa N, Asanuma M, et al. Effects of the acetylcholinesterase inhibitor ENA-713 on ischemia-induced changes in acetylcholine and aromatic amine levels in the gerbil brain. Arch Int Pharmacodyn Ther. 1993;323:85-96.
10. Kimura S, Saito H, Minami M, et al. Pathogenesis of vascular dementia in stroke-prone spontaneously hypertensive rats. Toxicology. 2000;153:167-178.
11. Meyer JS, Chowdhury MH, Xu G, et al. Donepezil treatment of vascular dementia. Ann N Y Acad Sci. 2002;977:482-486.
12. Kumar V, Anand R, Messina J, et al. An efficacy and safety analysis of Exelon in Alzheimer's disease patients with concurrent vascular risk factors. Eur J Neurol. 2000;7:159-169.
13. Moretti R, Torre P, Antonello RM, et al. Rivastigmine in subcortical vascular dementia. An open 22-month study. J Neurol Sci. 2002;203-204:141-146.
14. Erkinjuntti T, Kurz A, Gauthier S, et al. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: A randomised trial. Lancet. 2002;359:1283-1290.
15. Maelicke A, Samochocki M, Jostock R, et al. Allosteric sensitization of nicotinic receptors by galantamine, a new treatment strategy for Alzheimer's disease. Biol Psychiatry. 2001;49:279-288.
16. Samochocki M, Zerlin M, Jostock R, et al. Galantamine is an allosterically potentiating ligand of the human alpha4/beta2 nAChR. Acta Neurol Scand Suppl. 2000;176:68-73.
17. Tariot PN, Solomon PR, Morris JC, et al, for the Galantamine USA-10 Study Group. A 5-month, randomized, placebo-controlled trial of galantamine in AD. Neurology. 2000;54:2269-2276.
18. Wilcock G, Lilienfeld S, Kershaw P. Galantamine produces cognitive, functional and global benefits in patients with Alzheimer's disease: Pooled data from two 6-month studies. In: Program and abstracts of the 6th International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; April 5-8, 2000; Stockholm, Sweden. Abstract.
19. Rockwood K, Mintzer J, Truyen L, et al. Effects of a flexible galantamine dose in Alzheimer's disease: A randomised, controlled trial. J Neurol Neurosurg Psychiatry. 2001;71:589-595.
20. Raskind MA, Peskind ER, Wessel T, Yuan W, for the Galantamine USA-1 Study Group. Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. Neurology. 2000;54:2261-2268.
21. Wilcock GK, Lilienfeld S, Gaens E, for the Galantamine International-1 Study Group. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: Multicentre randomised controlled trial. BMJ. 2000;321:1445-1449.
22. Roman GC, Tatemichi TK, Erkinjuntti T, et al. Vascular dementia: Diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology. 1993;43:250-260.
23. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939-944.
24. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state." A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189-198.
25. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry. 1984;141:1356-1364.
26. Gelinas I, Gauthier L, McIntyre M, Gauthier S. Development of a functional measure for persons with Alzheimer's disease: The Disability Assessment for Dementia. Am J Occup Ther. 1999;53:471-481.
27. Cummings JL. The Neuropsychiatric Inventory: Assessing psychopathology in dementia patients. Neurology. 1997;48(Suppl 6):S10-S16.
28. Cummings JL, Mega M, Gray K, et al. The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia. Neurology. 1994;44:2308-2314.
29. Gillings D, Koch G. The application of the principle intention-to-treat to the analysis of clinical studies. Drug Inf J. 1991;25:411-424.
30. Torfs K, Feldman H. 12-Month decline in cognitive and daily function in patients with mild-to-moderate Alzheimer's disease treated with placebo in two randomized studies. In: Program and abstracts of the 7th International Alzheimer Congress; July 9-18, 2000; Washington, DC. Abstract.
31. Marcusson J, Rother M, Kittner B, et al, for the European Propentofylline Study Group. A 12-month, randomized, placebo-controlled trial of propentofylline (HWA 285) in patients with dementia according to DSM III-R. Dement Geriatr Cogn Disord. 1997;8:320-328.
32. Rother M, Erkinjuntti T, Roessner M, et al. Propentofylline in the treatment of Alzheimer's disease and vascular dementia: A review of Phase III trials. Dement Geriatr Cogn Disord. 1998:9(Suppl 1):36-43.
33. Feldman H, Sauter A, Donald A, et al. The Disability Assessment for Dementia Scale: A 12-month study of functional ability in mild to moderate severity Alzheimer disease. Alzheimer Dis Assoc Disord. 2001;15:89-95.